Form 4: Nuvation Bio CRO Kerry Wentworth Granted Stock Options

Nuvation Bio's Chief Regulatory Officer, Kerry Wentworth, was granted 748,130 stock options and holds 53,000 shares of Class A Common Stock.

Summary

• Kerry Wentworth, Chief Regulatory Officer of Nuvation Bio Inc. (NUVB), reported beneficial ownership changes.
• Wentworth was granted stock options to purchase 748,130 shares of Class A Common Stock.
• The options have an exercise price of $5.91 per share.
• The options begin vesting on February 27, 2027, with 25% vesting on the one-year anniversary of the grant date, and the remainder vesting monthly over the subsequent 36 months, subject to continuous service.
• The options expire on February 26, 2036.
• Following the reported transactions, Wentworth beneficially owns 53,000 shares of Class A Common Stock directly.
• This includes 3,000 shares acquired on November 19, 2025, through the 2021 Employee Stock Purchase Plan.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as it aligns executive incentives with long-term shareholder value and is a standard practice for executive retention, without indicating any immediate negative operational or financial issues.

Positives

• The grant of 748,130 stock options aligns the Chief Regulatory Officer's incentives with shareholder value creation.
• The options have a long expiration date of February 26, 2036, providing ample time for potential value realization.
• The vesting schedule encourages long-term commitment and continuous service from a key executive.

Negatives

• The issuance of new stock options could lead to potential future dilution for existing shareholders if exercised.
• The exercise price of $5.91 per share means the options only have intrinsic value if the stock price rises above this level.

Risks

• The value of the stock options is contingent on Nuvation Bio's stock price performance, which is subject to market fluctuations and company-specific risks.
• Future dilution from the exercise of these and other outstanding options could impact earnings per share.

Future Outlook

The stock options granted to Kerry Wentworth are subject to a vesting schedule, with 25% vesting on February 27, 2027, and the remainder vesting monthly over the subsequent 36 months, contingent on continuous service. This structure incentivizes long-term executive retention and performance.

Industry Context

StockSavvy.ai notes that executive equity grants, such as stock options, are a standard component of compensation packages in the biotechnology and pharmaceutical industries. These grants are designed to align executive interests with long-term shareholder value creation and to retain key talent in a competitive sector.

Comparison to Industry Standards

• The grant of stock options with a multi-year vesting schedule is a common practice in the biotech industry, similar to compensation structures seen at companies like Moderna or BioNTech, where executive incentives are tied to long-term drug development milestones and market performance.
• The exercise price being set at the market price on the grant date is standard for incentive stock options, ensuring that the executive benefits only if the company's stock value appreciates.

Stakeholder Impact

• Shareholders: Potential future dilution if options are exercised, but also potential benefit from aligned executive incentives leading to increased company value.
• Employees: Reflects standard executive compensation practices, which can influence overall compensation philosophy.

Next Steps

• Continued service of Kerry Wentworth to meet vesting conditions for the stock options.
• Potential future exercise of options by Kerry Wentworth, subject to vesting and stock price performance.

Key Dates

Recommendation

This Form 4 filing details a routine executive compensation event (stock option grant) and does not provide new information about the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. It primarily serves to disclose insider ownership changes.

Keywords

Nuvation Bio, NUVB, Kerry Wentworth, Chief Regulatory Officer, Stock Options, SEC Form 4, Beneficial Ownership, Equity Grant, Executive Compensation, Employee Stock Purchase Plan